To the Editor—In a recent in vitro study, Choi et al. [1] demonstrated that interleukin (IL)-18 inhibits human immunodeficiency virus (HIV) type 1 production in peripheral blood mononuclear cells (PBMC), and they concluded that IL-18 blocked HIV-1 production in PBMC through intermediate interferon-γ, suggesting that IL-18, as an inducer of the Th1-type response, may be a therapeutic candidate for the inhibition of HIV-1 replication in infected patients. In a previous study, Shapiro et al. [2] showed that, in vitro, IL-18 stimulated HIV-1 production in a chronically infected promonocytic cell line, U1. Subsequently, Klein et al. [3] found that IL-18 also stimulates HIV-1 production in an acutely infected Hut78 T cell line.